Effectiveness And Side Effects Of Alogliptin In Type 2 Diabetes Mellitus Patients. Article Review
Abstract
Diabetes mellitus is defined as a group metabolic disorders caused by multiple aetiology, characterized by hyperglycaemia with disorders of carbohydrate, protein and fat metabolism resulting from defects in insulin secretion, insulin action, or both. The clinical diagnosis of diabetes might manifest as polyuria, polydipsia, and unexplained weight loss, and is confirmed by measurement of abnormal hyperglycaemia. In type 2 diabetes progressive loss of b-cell insulin secretion often causes insulin resistance. Insulin resistance manifestations include increased lipolysis and free fatty acid production, increased hepatic glucose production, and decreased glucose intake to skeletal muscle. Alogliptin is an oral antidiabetic drug from class of dipeptidyl peptidase-4 (DPP-4) inhibitors for therapy in T2DM patients. Alogliptin can be used as monotherapy or combined with other anti diabetic agents such as metformin, sulfonylureas (glyburide), pioglitazone, and insulin. Based on several studies alogliptin shows low risk of the occurrence of side effects, such as hypoglycemia, edema, weight gain, RA, joint pain and cardiovascular events. The purpose of this review is to update clinical information about the effectiveness and side effects of alogliptin as diabetic therapy in T2DM patients.References
Soelistijo., Soebagijo A., Hermina Novida., Achmad Rudijanto, Pradana Soewondo, and Ketut Suastika., Konsessus Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Di Indonesia., PB PERKENI., (2015), 1: 1-82.
WHO., Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO/IDF consultation, WHo library Cataloguing-in-publication Data, 1 (2006): 1-46
WHO., Global Report on Diabetes., WHO Library Cataloguing-in-Publication Data Global., (2016):1-88.
KEMENKES., (2009, November Minggu). Tahun 2030 Prevalensi Diabetes Melitus Di Indonesia Mencapai 21,3 Juta Orang. Retrieved Mei Jumat, 2019.,fromhttp://www.depkes.go.id/article/view/414/tahun-2030-prevalensi-diabetes-melitus-di-indonesia-mencapai-213-juta-orang.html.
Association, American Diabetes., Diabetes Care., The Journal Of Clinical And Applied Research And Education., 40 (2017) 1: 1–135.
Wu, Yanling, Yanping Ding, Yoshimasa Tanaka, and Wen Zhang., Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention., International Journal of Medical Sciences., 11 (2014) 11: 1185–1200
Dendup, Tashi, Xiaoqi Feng, Stephanie Clingan, and Thomas Astell-Burt., Environmental Risk Factors for Developing Type 2 Diabetes Mellitus: A Systematic Review., International Journal of Environmental Research and Public Health., 15 (2018) 78: 1–25.
Papatheodorou, Konstantinos, Maciej Banach, Eleni Bekiari, Manfredi Rizzo, and Michael Edmonds., Complications of Diabetes 2017., Journal of Diabetes Research., (2018): 1–4
Tuttolomondo, Antonino., Diabetic Foot Syndrome: Immune-Inflammatory Features as Possible Cardiovascular Markers in Diabetes., World Journal of Orthopedics., 6 (2015) 1: 1-12.
MarÃn-Peñalver, Juan José, Iciar MartÃn-Timón, Cristina Sevillano-Collantes, and Francisco Javier del Cañizo-Gómez., Update on the Treatment of Type 2 Diabetes Mellitus.., World Journal of Diabetes., 7 (2016) 17: 354-359.
Garber, Alan J., Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, and Michael A. Bush., Consensus Statement By the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2016 Executive Summary., Endocrine Practice., 22 (2016) 1: 207–38.
Grimshaw, Charles E., Andy Jennings, Ruhi Kamran, Hikaru Ueno, Nobuhiro Nishigaki, and Takuo Kosaka., Trelagliptin (Syr-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (Dpp-4) via a Non-Covalent Mechanism., PLoS ONE., 11 (2016) 1: 1–14.
McKeage, Kate., Trelagliptin: First Global Approval., International Publishing Switzerland., 75 (2015) 17 :1-4.
Jarvis, Courtney I., Adriana Cabrera, and Derek Charron., Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus, Annals of Pharmacotherapy., 47 (2013) 11: 1532–1539.
Saisho, Yoshifumi., Alogliptin Benzoate for the Treatment of Type 2 Diabetes., Dovepress., 11 (2015), 229–243.
Baynest, Habtamu Wondifraw., Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus., Journal of Diabetes and Metabolism., 6 (2015) 5: 1–9.
Association, American Diabetes., Diagnosis and Classification of Autoimmune Diabetes Mellitus., Care Diabetes Journals., 33 (2010) 1: 62–69.
Kharroubi, Akram T, and Hisham M Darwish., Diabetes Mellitus: The Epidemic of the Century., World Journal of Diabetes., 6 (2015) 6: 850–67.
Punthakee, Zubin, Ronald Goldenberg, and Pamela Katz., Definition, Classification and Diagnosis of Diabetes, Prediabetes and Metabolic Syndrome., Canadian Journal of Diabetes., 42 (2018):10–15.
Zheng, Yan, Sylvia H Ley, and Frank B Hu., Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications., Nature Reviews Endocrinology., 14 (2018) 2: 88–98.
Roglic, Gojka, and Nigel Unwin., Mortality Attributable to Diabetes: Estimates for the Year 2010., Diabetes Research and Clinical Practice., 87 (2010) 1: 15–19.
Cho, N. H., J. E. Shaw, S. Karuranga, Y. Huang, J. D. da Rocha Fernandes, and A. W. Ohlrogge., IDF Diabetes Atlas: Global Estimates of Diabetes Prevalence for 2017 and Projections for 2045., Diabetes Research and Clinical Practice., 138 (2018)1: 271–81.
Ozougwu, J. C, K. C Obimba, C. D Belonwu, and C. B Unakalamba., The Pathogenesis and Pathophysiology of Type 1 and Type 2 Diabetes Mellitus., Journal of Physiology and Pathophysiology., 4 (2014) 4: 46–57.
Kaku, Kohei., Pathophysiology of Type 2 Diabetes and Its Treatment Policy., Japan Medical Association Journal., 53 (2010) 1: 41–46.
Kahn, Steven E, Mark E Cooper, and Stefano Del Prato., Pathophysiology and Treatment of Type 2 Diabetes : Perspectives on the Past, Present and Future., The Lancet., 383 (2014) 9923: 1068–83.
Skyler, Jay S., George L. Bakris, Ezio Bonifacio, Tamara Darsow, Robert H. Eckel, and Leif Groop., Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis., Diabetes, 66 (2017): 241–55.
Kahn, S. E., The Relative Contributions of Insulin Resistance and Beta-Cell Dysfunction to the Pathophysiology of Type 2 Diabetes., Diabetologia, 46 (2003) 1: 3–19.
Montagnani, Monica, Lingamanaidu V. Ravichandran, Hui Chen, Diana L. Esposito, and Michael J. Quon., Insulin Receptor Substrate-1 and Phosphoinositide-Dependent Kinase-1 Are Required for Insulin-Stimulated Production of Nitric Oxide in Endothelial Cells., Molecular Endocrinology., 16 (2002) 8: 1931–1942.
Lee, Jin Hee, and Louis Ragolia., AKT Phosphorylation Is Essential for Insulin-Induced Relaxation of Rat Vascular Smooth Muscle Cells., American Journal of Physiology-Cell Physiology., 291 (2006) 6: 1355–65.
Kulkarni, Rohit N., and Andrew F. Stewart., Summary of the Keystone Islet Workshop (April 2014): The Increasing Demand for Human Islet Availability in Diabetes Research., Diabetes, 63 (2014) 12: 3979–81.
Guillausseau, P. J, T Meas, M Virally, M. Laloi Michelin, V Medeae, and J. P Kevorkian., Abnormalities in Insulin Secretion in Type 2 Diabetes Mellitus., Diabetes and Metabolism., 34 (2008) 1: 43–48.
Seino, Susumu, Tadao Shibasaki, and Kohtaro Minami., Dynamics of Insulin Secretion in Obesity., Journal of Clinical Ivestigation., 121 (2011) 6: 2118–2125.
Baetta, Roberta, and Alberto Corsini., Pharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences., Drugs., 71 (2011) 11: 1441–1467.
Russell-Jones, David, and Stephen Gough., Recent Advances in Incretin-Based Therapies., Clinical Endocrinology., 77 (2012) 4: 489–99.
Dineen, L, C Law, R Scher, and E Pyon., Alogliptin (Nesina) for Adults with Type-2 Diabetes., Pharmacy and Theraupetics., 39 (2014) 3: 186–202.
Holland, Daniel Q., and Joshua J. Neumiller., Alogliptin in Combination with Metformin and Pioglitazone for the Treatment of Type 2 Diabetes Mellitus., Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy., 7 (2014) 1: 277–88.
Gibbs, John P., Jill Fredrickson, Todd Barbee, Itzela Correa, Brian Smith, and Shao Lee Lin., Quantitative Model of the Relationship between Dipeptidyl Peptidase-4 (DPP-4) Inhibition and Response: Meta-Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results., Journal of Clinical Pharmacology., 52 (2012) 10: 1494–1505.
Berhan, Asres, and Yifru Berhan., Efficacy of Alogliptin in Type 2 Diabetes Treatment: A Meta-Analysis of Randomized Double-Blind Controlled Studies., BMC Endocrine Disorders., 13 (2013) 9 : 1–10.
Chen, Xiao Wu, Zhi Xu He, Zhi Wei Zhou, Tianxin Yang, Xueji Zhang, and Yin Xue Yang., An Update on the Clinical Pharmacology of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin Used for the Treatment of Type 2 Diabetes Mellitus., Clinical and Experimental Pharmacology and Physiology., 42 (2015) 12: 1225–1238.
Neumiller, Joshua J., and Daniel Q. Holland., Alogliptin + Metformin Combination for the Treatment of Type 2 Diabetes Mellitus., Expert Review of Endocrinology and Metabolism., 11 (2015) 1: 1–11.
Ji, Linong, Ling Li, Jian Kuang, Tao Yang, Dong Jun Kim, and Azidah A. Kadir., Efficacy and Safety of Fixed-Dose Combination Therapy, Alogliptin plus Metformin, in Asian Patients with Type 2 Diabetes: A Phase 3 Trial., Diabetes, Obesity and Metabolism., 19 (2016) 5: 754–758
Kay, Stephen, Amanda Strickson, Jorge Puelles, Ross Selby, Eugene Benson, and Keith Tolley., Comparative Effectiveness of Adding Alogliptin to Metformin Plus Sulfonylurea with Other DPP-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis., Diabetes Therapy., 8 (2017) 2: 251–273
Aoki, Chie, Kunihiro Suzuki, Hisamoto Kuroda, and Masaaki Sagara., Fixed-Dose Combination of Alogliptin/Pioglitazone Improves Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Independent of Body Mass Index., Nagoya Journal of Medical Science., 79 (2017) 1: 9–16.
Rosenstock, J., M. S. Rendell, J. L. Gross, P. R. Fleck, C. A. Wilson, and Q. Mekki., Alogliptin Added to Insulin Therapy in Patients with Type 2 Diabetes Reduces HbA1c without Causing Weight Gain or Increased Hypoglycaemia., Diabetes, Obesity and Metabolism., 11 (2009) 12: 1145–52.
Kaku, Kohei, Mikiko Mori, Tatsuhiro Kanoo, and Masafumi Katou., Efficacy and Safety of Alogliptin Added to Insulin in Japanese Patients with Type 2 Diabetes : A Randomized , Double-Blind , Followed by an Open-Label , Long-Term Extension Phase., Expert Opinion Pharmacotherapy., 15 (2014) 15: 2121–30.
Kristin, Erna., Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus., Journal of Medical Sciences., 48 (2016) 2: 1–9.
Kathe, Niranjan, Anuj Shah, Qayyim Said, and Jacob T. Painter., DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case–Control Study., Diabetes Therapy., 9 (2018) 1: 141–151.
FDA., FDA Warns That DPP-4 Inhibitors for Type 2 Diabetes May Cause Severe Joint Pain., Food and Drug Administration, Drug Safety Comminication., 2015, 2–5.
Younk, Lisa M., Elizabeth M. Lamos, and Stephen N. Davis., Cardiovascular Effects of Anti-Diabetes Drugs., Expert Opinion on Drug Safety., 15 (2016) 9: 1239–1257.
Cefalu, William T., Sanjay Kaul, Hertzel C. Gerstein, Rury R. Holman, Bernard Zinman, and Jay S. Skyler., Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Ref Lections From a Diabetes Care Editors’ Expert Forum., Diabetes Care., 41 (2018) 1: 14–31.
.png)
